Tuesday 30th September 2014

**Targeting of drugs for cancer therapy**

**Chairperson: Dr Klaus Bosslet**

8.00  Armed Antibodies Targeting Tumor Antigens: Selecting the Right Tool for the Job.
*Dr James Legg, Senior Scientist, Medimmune, UK.*

8.20  RG7787 - A cytolitic fusion protein based on a de-immunised variant of Pseudomonas Exotoxin (PE)
*Dr Klaus Bosslet, Head Discovery Oncology, Penzberg, Roche Diagnostics GmbH, Germany.*

8.40  Preclinical profile and CMC properties of SYD985 – A novel HER2-targeting ADC.
*Dr Ruud Coumans, Project Leader, Synthon, The Netherlands.*

9.00  Pretargeted radioimmunoimaging and – therapy: from mice to men.
*Professor Dr Otto Boerman, Head Preclinical Research, Radboud University Medical Center, The Netherlands.*

9.20  Antibody Drug Conjugates (ADCs) Utilizing Maytansinoid Technology: From Bench to Kadycyla and Beyond.
*Dr John M. Lambert, Executive VP and CSO, ImmunoGen, Inc., USA.*

**Novel Therapeutic Antibodies**

**Chairperson: Dr Volker Schellenberger**

9.40  ARGX-110, a clinical stage, neutralizing, humanized monoclonal antibody to the human CD70 antigen with enhanced.
*Dr Karen Silence, arGEN-X BVBA, Belgium.*

10.00  ARGX-111, a defucosylated antagonistic anti-MET antibody, displays potent anti-tumor activity through enhanced.
*Dr Michael Saunders, Senior Director Targets and Programmer, arGEN-X BVBA, Belgium.*

10.20  Comprehensive functional screening of the CLL surfaceome identifies FcgRIIb as a promising target, and FcgRIIb-blocking antibodies modulate antibody therapy in vivo.
*Dr Bjorn Frendeus, CSO, Bioinvent International (Publ) Sweden.*

10.40  Refreshments and Networking

11.00  Using antibody fragments to assist structural biology, for intracellular vaccination and for drug discovery.
*Professor Terrence H. Rabbitts, MRV, University of Oxford, UK.*

11.20  Novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis and a mechanism of drug-resistance.
*Dr Sergej M. Kiprijanov, Director of Biologics Research and Development, BerGenBio, Norway.*

*Dr Dimiter S. Dimitrov, NCI/NIH, USA.*

12.00  Strategies for enhancing the efficacy of HER2-targeted anti-cancer therapies.
*Dr Gail Lewis Phillips, Senior Scientist, Genentech, Inc., USA.*

**Future advances in novel biologics platform**

**Chairperson: Dr Mike Romanos**

12.20  The application of nanotechnology to radioimmunotherapy and radioimmunodiagnostics.
*Professor Katherine A. Vallis, Department of Oncology, University of Oxford, UK.*

12.40  Title to be announced.
*Dr Louis Boon, CSO, Bioceros, The Netherlands.*

1.00  Lunch

2.00  Combining Phage and Yeast-Display: New developments in Antibody Discovery and Optimisation.
*Dr Vera Malkenthin, Chief Scientist, ABCheck S.r.o. Pizen, Czech Republic.*

2.20  Use of molecular imaging with monoclonal antibodies in drug development.
*Professor Elisabeth E.G.E.de Vries, Department of Oncology, University of Groningen, The Netherlands.*

2.40  Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3.
*Dr Neil Clarke, Director, Biopharm Discovery Group, RD Biopharm, R&D, GSK, UK.*

Contact

Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH, UK
Tel: +44 (0) 7960 139108
Fax: +44 (0) 1628 671448
Email: gsub@subramanian.org.uk
Web: www.subramanian.org.uk
To reserve your place please complete the registration form in BLOCK LETTERS and post it with full remittance to: Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH or, email to gsub@subramanian.org.uk

<table>
<thead>
<tr>
<th>Full Name</th>
<th>...........................................</th>
<th>Job Title</th>
<th>...........................................</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Organisation</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Address</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Postcode</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Country</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tel</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Email</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Any Special Requirement (Dietary)</td>
<td>...........................................</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Questions or Comments</td>
<td>...........................................</td>
</tr>
</tbody>
</table>

**Registration Fees:**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full attendance including all meals and accommodation</td>
<td>£700</td>
</tr>
<tr>
<td>Attendance with all meals and no accommodation</td>
<td>£575</td>
</tr>
</tbody>
</table>

**Method of payment:**

Cheques payable to Dr. G. Subramanian in Pound Sterling only and drawn on a UK based bank or by Direct bank transfer. For other methods please see www.subramanian.org.uk

**Cancellation**

Should you be unable to attend, a substitute delegate is welcomed at no extra charge.

---

**Monday 29th September 2014**

- **12.00** Registration
- **12.55** Opening remarks Dr G Subramanian.
- **1.00** Emerging Therapeutic Approaches – Antibody, Peptides and Oligonucleotides
  **Chairperson:** Dr Rakesh Dixit
  **Human single domain antibodies and their application in oncology,**
  *Dr Mike Romanos, CEO; CrescendoBiosciences, UK.*
- **1.20** Bicyclic peptides to target protein-protein interactions: application to payloads in oncology
  *Dr Christophe Bonny, CSO; Bicyclerapeutics.UK.*
- **1.40** Therapeutic Oligonucleotides – progress towards a viable drug platform for tackling intractable targets in oncology
  *Dr David Blakey, Chief Scientist Oncology, AstraZeneca, UK.*
- **2.00** Targeted Drug Delivery via XTEN, a protein-based polymer with precisely controlled chemical composition.
  *Dr Volker Schellenberger, President and CEO, Amunix Operating Inc., USA.*
- **2.20** The Nanobody platform: Opportunity for next generation therapeutics.
  *Dr Carlo Boutton, Director Technology and Information management, Ablynx, Belgium.*
- **2.40** RNA activation.
  *Professor Nagy A. Habib, Imperial College, London, UK.*
- **3.00** Exploiting the Immune System and stromal cancer therapy
  **Chairperson:** Dr Robert Wilkinson
  **Blocking antibodies against a novel immune checkpoint target,**
  *Dr Bas Van Der Wonning, arGEN-X BVBA, Belgium.*
- **3.20** Refreshments and Networking.
- **4.00** Immune activation biologics leading self enhanced war on cancer.
  *Dr Rakesh Dixit, VP, R&D, Medimmune, USA.*
- **4.20** ErbB-Targeted CAR T Cell Immunotherapy of Cancer: A Strategy to Maximize the Window of Therapeutic Opportunity.
  *Dr John Maher, Kings College, London, UK.*
- **4.40** Manipulating cancer related inflammation in the tumour microenvironment
  *Dr Alexander Duncan, CEO., Actigen Ltd, UK.*
- **5.00** Targeting tumor-associated macrophages with a novel anti-CSF-1R antibody in cancer patients.
  *Dr Klaus Bosslet, Head Discovery oncology Penzberg, Roche Diagnostics gmbH, Germany.*
- **5.20** Targeting the immune system to combat cancer.
  *Dr Robert Wilkinson, Director of oncology, Medimmune, UK.*
- **5.40** Bi-specific Approaches for Therapy
  **Chairperson:** Dr Ezio Bonvini
  **Advancing bi-specific DART molecules for the treatment of liquid cancers**
  *Dr Ezio Bonvini, SrVP, Macrogenics.Inc., USA.*
- **6.00** Therapeutic applications of bi-specific DARTs for solid tumors: concepts and validation
  *Dr Paul Moore, Senior Director, Macrogenics. Inc., USA.
- **6.20** Rapid and Systematic Design and Manufacture of Bispecific antibodies and Homogeneous Antibody Drug Conjugates by Cell-free Protein Production
  *Dr Trevor J.Hallam, CSO, Sutro Biopharm, USA.*
- **6.40** TandAb platform produces bispecific antibodies for killing cancer cells.
  *Dr Eugene Zhukovsky, CSO, Affimed Therapeutics AG, Germany.*
- **7.00** Single domain antibodies: from conformational sensors to bispecific antibodies for immunotherapy.
  *Dr Patrik Chames, INSERM, France.*